Surface Bioadvances Inc

Biomyx Inc. is a private biotechnology company based in San Diego, California, established in 2002. The company focuses on advancing biosciences by creating innovative technologies that enhance the study of gene functions and improve the efficiency of biomedical research through high-quality, user-friendly products. Specializing in functional genomics, Biomyx offers a range of technologies and products that facilitate studies on gene functions in mammalian cells, particularly in cellular signal transduction. Their expertise also extends to molecular biology, cell biology, and biochemistry, providing tailored assay development services on a fee-for-service basis. Generated from the website

Structure Based Design (SBD) is a leading company based in San Diego, CA, specializing in drug discovery and development. With a strong focus on utilizing cutting-edge technology and innovative approaches, SBD is dedicated to providing rapid and effective solutions for finding drug candidates. Offering a wide range of services, including crystal structure determination, protein manufacturing, assay development, and fragment-based drug discovery, SBD has established itself as a trusted partner in the pharmaceutical industry. Their expertise in kinase drug discovery, GPCR drug discovery, and antibody discovery further enhances their capabilities in delivering high-quality results. With a commitment to excellence and a customer-centric approach, SBD is poised to make significant contributions to the field of drug development.Generated from the website

MD2 Biosciences Inc. is a San Diego-based biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics primarily focused on oncology. With a commitment to addressing significant unmet medical needs, the company aims to develop best-in-class or first-in-class programs to enhance and extend the lives of patients suffering from various cancers. Utilizing innovative artificial intelligence techniques in their drug discovery and optimization processes, MD2 Biosciences has created a unique platform that identifies small-molecule hits for flat proteins. This cutting-edge approach, combined with their expertise in medicinal chemistry, allows the company to generate novel lead compounds tailored for effective administration routes, including oral and intravenous options, while also facilitating central nervous system delivery. Generated from the website